Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Grows By 45.5%

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 83,800 shares, a growth of 45.5% from the December 15th total of 57,600 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is presently 2.2 days. Approximately 2.4% of the company’s shares are short sold.

TriSalus Life Sciences Stock Down 0.1 %

TLSI traded down $0.00 during trading on Thursday, hitting $4.80. The company’s stock had a trading volume of 10,689 shares, compared to its average volume of 20,829. The business’s 50 day simple moving average is $4.39 and its 200-day simple moving average is $4.78. The firm has a market cap of $146.26 million, a PE ratio of -1.93 and a beta of 0.51. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42.

Analyst Upgrades and Downgrades

TLSI has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price on the stock. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm assumed coverage on shares of TriSalus Life Sciences in a report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective for the company. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price on the stock. Finally, Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.79.

Insider Buying and Selling at TriSalus Life Sciences

In related news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now directly owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 70,012 shares of company stock valued at $281,235 in the last 90 days. Insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors have recently bought and sold shares of the stock. Highbridge Capital Management LLC bought a new stake in TriSalus Life Sciences during the second quarter valued at about $1,184,000. Duquesne Family Office LLC lifted its position in shares of TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares in the last quarter. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $66,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $184,000. Finally, Vestcor Inc bought a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $108,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.